Single-cell multi-region transcriptional and epigenomic dissection of VCID.

VCID 的单细胞多区域转录和表观基因组解剖。

• 批准号: 10532050
• 负责人: Myriam Heiman
• 金额: $ 305.85万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10532050
• 关键词: Address; Affect; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; Anatomy; Area; Arterial Disorder; Atherosclerosis; Atlases; Autopsy; Basal Ganglia; Biological Markers; Blood Vessels; Brain region; CADASIL; Cardiovascular Diseases; Cell Communication; Cell Nucleus; Cells; Cerebral Amyloid Angiopathy; Cerebral small vessel disease; Cerebrovascular Disorders; Cerebrum; Computer Analysis; Coupled; DNA; Data; Data Set; Dementia; Diagnosis; Disease; Disease Progression; Dissection; Enhancers; Etiology; Gene Expression Regulation; Genes; Genetic; Genetic Models; Genetic Transcription; Health Care Costs; Heart; Heart Diseases; Human; Hypertension; Image; Immune; Impaired cognition; Individual; Joints; Link; Maps; Mediation; Medical; Molecular; Morbidity - disease rate; Nerve Degeneration; Neurons; Occipital lobe; Pathologic; Pathology; Pathway interactions; Patients; Phenotype; Prefrontal Cortex; Prevalence; Prevention; Protocols documentation; Public Health; Resolution; Sampling; Severities; Small Nuclear RNA; Sterile coverings; Stroke; Subcortical Infarctions; Subcortical Leukoencephalopathy; Therapeutic; Tissues; Transcription Alteration; Variant; Work; aging brain; aging population; base; cell type; cerebrovascular; cerebrovascular lesion; clinical diagnosis; clinically relevant; computer framework; effective therapy; epigenome; epigenomics; genetic variant; heart disease prevention; hypertensive; imaging study; insight; loved ones; male; mortality; multiple omics; novel; novel therapeutics; putamen; sex; success; therapeutic development; trait; transcriptome sequencing; transcriptomics; vascular cognitive impairment and dementia; white matter

Abstract Alzheimer’s disease (AD) and AD-related dementias (ADRDs) are major drivers of mortality, morbidity, and health care costs for patients and their loved ones, due to the aging population, lack of predictive diagnosis, and lack of effective treatments or prevention. Vascular contributions to cognitive impairment and dementia (VCIDs) are key contributors to AD and ADRDs and manifest through diverse cerebrovascular lesions, including atherosclerosis, microinfarcts, and small vessel strokes. VCIDs include cerebral small vessel disease (CSVD), cerebral amyloid angiopathy (CAA), and a monogenic familial form of CSVD (CADASIL, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy). Understanding the mechanisms and drivers of VCID will enable new biomarkers and therapeutics, similar to the success of addressing cardiovascular disease and hypertension in heart disease. To understand the cellular mechanisms underlying VCID across brain regions, cell types, pathology, and molecular pathways, we perform high- resolution profiling of epigenomic and transcriptional alterations in post-mortem CNS samples from both sporadic and genetic VCID patients. Aim 1: We profile single-nucleus RNA-sequencing (snRNA-seq) and DNA accessibility (snATAC-seq) to create a transcriptional and epigenomic atlas of VCID across diagnoses, brain regions, cell types, sexes, and individuals. Aim 2: We create an atlas of SVD-associated changes in genes, modules, pathways, and cell-cell interactions. Aim 3: We predict candidate driver genes, regulators, and pathways using causality analyses across temporal and genetic models, and we validate our results experimentally using imaging studies. The successful execution of our studies will delineate clinically-relevant VCID biomarkers and therapeutics across sporadic and genetic VCID, enabling us to dissect their common and distinct molecular circuits, across four affected CNS region and all major cell types within them, and capturing an unprecedented level of complexity and enabling rich computational comparisons. The datasets generated and the computational analyses will provide invaluable insights for addressing the pressing medical need of VCIDs, their temporal, region-specific, and cell-type-specific changes, which can help guide new therapeutics.

抽象的 阿尔茨海默病 (AD) 和 AD 相关痴呆 (ADRD) 是死亡率、发病率和死亡率的主要驱动因素 由于人口老龄化、缺乏预测诊断，患者及其亲人的医疗保健费用， 缺乏有效的治疗或预防导致血管损伤和痴呆。 (VCID) 是 AD 和 ADRD 的关键因素，并通过不同的脑血管病变表现出来， 包括动脉粥样硬化、微梗塞和小血管中风 VCID 包括脑小血管疾病。 (CSVD)、脑淀粉样血管病 (CAA) 和单基因家族性 CSVD（CADASIL、脑淀粉样血管病） 常染色体显性遗传性动脉病伴皮质下梗死和白质脑病）。 VCID 的机制和驱动因素将实现新的生物标志物和治疗方法，类似于 解决心血管疾病和心脏病中的高血压 了解细胞机制。 跨大脑区域、细胞类型、病理学和分子途径的潜在 VCID，我们表现出色 对死后中枢神经系统样本的表观基因组和转录改变进行分辨率分析 目标 1：我们对散发性和遗传性 VCID 患者进行单核 RNA 测序 (snRNA-seq) 和 DNA 分析。 可访问性 (snATAC-seq) 创建跨诊断、大脑的 VCID 转录和表观基因组图谱 目标 2：我们创建 SVD 相关基因变化图谱。 目标 3：我们预测候选驱动基因、调节因子和 使用跨时间和遗传模型的因果关系分析的途径，并验证我们的结果 使用成像研究进行实验，我们的研究的成功执行将描述临床相关性。 跨散发性和遗传性 VCID 的 VCID 生物标志物和治疗方法，使我们能够剖析它们的共同点 和不同的分子回路，跨越四个受影响的中枢神经系统区域及其内的所有主要细胞类型，以及 捕获前所未有的复杂性并实现丰富的计算比较。 生成的数据和计算分析将为解决紧迫的医疗问题提供宝贵的见解 VCID 的需求及其时间、区域特定和细胞类型特定的变化，这可以帮助指导新的 疗法。